Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer

Table 1 Detailed information of pancreatic cancer patients treated with stereotactic body radiotherapy

Patient	Sex	T	N	M	CA19-9	Dose/No. of fractions	Live/dead	Survival time (mo)	Toxicity
1	Female	4	0	0	Positive	36 Gy/3	Live	4	G1
2	Male	3	0	0	Negative	45 Gy/4	Dead	9
3	Male	3	1	1	Negative	48 Gy/4	Live	2	G1
4	Male	3	0	0	Positive	46 Gy/4	Dead	2
5	Male	3	1	1	Positive	46 Gy/4	Dead	8
6	Male	3	1	1	Positive	30 Gy/3	Live	8	G1
7	Female	3	0	0	Positive	36 Gy/3	Dead	4
8	Female	3	1	0	Negative	31.5 Gy/3	Live	17
9	Female	3	1	1	Negative	33 Gy/3	Dead	5
10	Male	3	0	1	Positive	36 Gy/3	Dead	9	G1
11	Male	3	0	1	Positive	35 Gy/3	Dead	14
12	Female	4	1	1	Positive	33 Gy/3	Dead	9
13	Female	4	0	1	Positive	36 Gy/3	Dead	3	G1
14	Male	3	0	0	Positive	36 Gy/3	Live	6
15	Male	3	0	1	Negative	40 Gy/4	Dead	3
16	Female	3	0	1	Positive	45 Gy/4	Live	15	G1
17	Male	3	1	1	Negative	33 Gy/3	Dead	17
18	Male	3	0	1	Positive	36 Gy/3	Dead	2	G2
19	Male	3	1	1	Positive	36 Gy/3	Dead	2
20	Male	3	1	0	Negative	42 Gy/4	Dead	3
21	Male	3	0	0	Negative	33 Gy/3	Live	3	G1
22	Male	4	1	1	Positive	40 Gy/4	Live	1
23	Male	3	1	0	Positive	46 Gy/4	Live	25
24	Male	3	1	1	Negative	48 Gy/4	Dead	9
25	Male	3	0	1	Positive	40 Gy/4	Live	9	G1

CA19-9: Carbohydrate antigen 19-9.

Table 2 Characteristics of pancreatic cancer patients treated with stereotactic body radiotherapy

Characteristic	n
Sex
Male	18
Female	7
Age, yr	Median 63 (range: 44-80)
Stage1
T3	21
T4	4
N0	13
N1	12
M0	9
M1	16
Dose (Gy)/No. of fractions
30-36 Gy/3	14
40-48 Gy/4	11
Carbohydrate antigen 19-9
Positive	16
Negative	9
Primary location of tumor
Head of pancreas	20
Body or tail of pancreas	5

¹According to 2010 AJCC staging system.

Table 3 Summary of treatment regimen, local control, progression-free survival, overall survival and late toxicity in previous studies compared with the present study

Ref.	No. of patients	SBRT dose (Gy/No. of fractions)	Gemcitabine-based chemotherapy	LC (%)	PFS (mo)	OS (mo)	Toxicity (≥G2) (%)
Didolkar et al[17]	85	15-30 Gy/3	Sequential	91.7	-	18.6 from diagnosis 8.6 from SBRT	22
Polistina et al[18]	23	30 Gy/3	Prior	82.6	7.3	10.6	None
Mahadevan et al[19]	39	24-36 Gy/3	Sequential	85	15	20 from diagnosis	9
Schellenberg et al[20]	16	25 Gy/1	Sequential	81	9	11.4 from diagnosis	47
Hoyer et al[21]	22	45 Gy/3	Sequential	57	4.8	5.7 from diagnosis	18
Koong et al[22]	15	15-25 Gy/1	No	77	2	11 from diagnosis	None
Chang et al[23]	77	25 Gy/1	Prior	84	-	11.4 from diagnosis	13
Schellenberg et al[24]	20	25 Gy/1	Sequential	94	9.2	11.8 from diagnosis	20
Rwigema et al[25]	71	18-25 Gy/1	No	64.8	-	10.3	10
Pollom et al[26]	167	25-33 Gy/1-5	Sequential or concurrent	-	-	13.6 from diagnosis	12.3
Moningi et al[27]	88	20-33 Gy/5	Gemcitabine, cisplatin, FOLFIRINOX or paclitaxel	-	9.8	18.4 from diagnosis	5.7 G23.4 G3
Gurka et al[28]	38	25-30 Gy/5	Gemcitabine, mFOLFOX or capecitabine	79	9.2	14.3 from diagnosis	-
Present study	25	30-36 Gy/3 or 42-48Gy/4	4 patients, Gemcitabine	-	-	M0 group 13.5 M1 group 8.5 from SBRT	4

LC: Local control; OS: Overall survival; PFS: Progression-free survival; SBRT: Stereotactic body radiotherapy.